IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Nanoparticles Used in Drugs Delivery System As Anticancer

Ms. Sakshi R. Potdar*
Ms. Sakshi V. Nanaware**
Ms. Tai Yele***
Department : Nanoscience And Nanotechnology
Organization : Institute Of Pharmaceutical Science And Research {For Girls}

- **Abstract**

Cancer,nanotherapeutics are developing quickly and are being used to overcome several problems with convent ional drug delivery systems, including poor oral absorption of nutrients, universal biological distribution and concentration, and a lack of water solubility. Unique nanotechnology targeting techniques have been developed as a result of d evelopments in materials science and protein engineering, which may give patien ts suffering from cancer new hope. Clinical usage of several therapeutic Nano carriers has been authorized.

- **Keywords: Nanoparticles, Nanocarriers; Drug delivery, Application of Nanoparticle Therapeutic Nanoparticles, Anticancer**

- **Introduction** With over 10 million cases being diagnosed each year, cancer continues to be one of th e most deadly diseases in the world[1].However, mortality has dropped in the last two years as a result of impro ved diagnostic tools and therapies as well as a better understanding of tumor biology[2].Currently available can cer therapies include s urgery, radiation, and chemotherapeutic medications, many of which also cause t he patient's healthy cells to die.The traditional chemotherapeutic agents also lack targeted action and are dispers ed nonspecifically throughout the body, affecting b oth cancerous and healthy cells. This limits the dose that can be delivered to tumo r cells and leads to suboptimal treatment because of excessive toxicities.One strat egy to address the lack of specialization intraditional chemotherapeutic drugs is molecular targeted therapy.[3]However, the development of resistance in cancer cells can pr otect them from the cytotoxicity of both more modern molecularly targeted treat ments as well as conventional chemotherapeutics [4].Nanoparticles can increase the intracellular concentration of medications in ca ncer cells while preventing toxicity in normal cells by employing both passive and active targeting tactics. Passive targeting takes advantage of the biological characteristics of tumors that e nable nanocarriers to build up in a tumor through higher permeation and preservat ion (EPR). A proactive approach accomplishes this by coupling molecules that attach to the overproduction of proteins or receptors on targeted cells to nanocarriers that c ontain chemotherapeutics [5][6].

By coupling compounds that attach to overproduced antibodies or transmitters on the plannedlevel cells with nanocarriers delivering chemotherapeutics, active methods accom plish this.

Although nanoparticles are excellent drug delivery vehicles, they nevertheless ha ve several drawbacks, including low oral metabolism, agitation in circulation, ins ufficient tissue distribution, and toxicity.
This review offers insight into how nanotechnology is being used as an essential i nstrument in malignancy studies as well as for medicinal purposes [7][8]. In this article, we will concentrate on the different types and properties of n anoparticles, how they are used as carriers of drugs to more efficiently kill cancer cells while also reducing or eli minating drug resistance, and how microscopic par ticles are being developed to enhance their beneficial effects and functionality in t he treatment of cancer.While nanoparticles are excellent drug delivery vehicles, t here are still a number of issues that need to be addressed, including low oral bioa vailability, circulatory instability, insufficient tissue distribution, and toxicity.
The reviews in this article offer perspective on how nanotechnology is used as an essential device in tumors inve stigations as well as Nano medicine. In this section,
we concentrate on the various kinds and properties of nanoparticles, how they are used as drug delivery mechani sms to more effectively kill cancer cells while also reducing or overcoming drug resistance, and how tiny particl es will be generated to enhance the effectiveness of therapy and functionality in the treatment of cancer.



Fig: Improving cancer treatment

Size and characteristics of nanoparticles Serving the delivery of medicines to the targeted tumor tissue requires nanoparticles to be abl e to stay in the circulatory system for an extended period of time without being re moved.
Depending on their size and surface properties, conventional surface particles and unaltered nanoparticles are usually captured in the bloodstream by the reticuloen dothelial system, which includes the liver and the spleen [9].
By modifying their size and surface properties, nanoparticles can be injected, and their fate managed.

Size

Another benefit of nanoparticles, along with their appearance, is that they can have different sizes.
The size of the nanoparticles utilized in the drug delivery system should be tiny e nough to avoid being caught by fixed macrophages that are ensconced in the retic uloendothelial system, such as the liver and the spleen, but large enough to preven t their quick leakage into arterial capillaries[10].The sinusoid in the spleen, the fe nestra of the Kuffer cells in the liver, and the separation connection between the e pithelial cells of the defective cancer vasculature can all range in size from 150 to 200 nm and 100 to 600 nm, res pectivel[10].

Surface properties

The surface properties of nanoparticles have a significant role in defining their lifetime and fate during circulation in relation t o macrophage capture. To avoid being captured by macrophages, hydrophilic surfaces for nanoparticles are preferred. Two techniques can be used to do this: first, coating t he surface of the nanoparticles with an aqueous polymer, like Peg, and second, shi elding them from opsonization by repelling proteins from the plasma. Alternative ly, blocking polymers with hydrophilic and hydrophobic regions can be used to cr eate nanoparticles[11].

Fig: Size and Surface characteristics

Targeted drug delivery system

A recent analysis examined the conformation of nanotechnology delivery styles for focused drug delivery. Either laboriously or passively, targeted distribution can be fulfilled[12] In order to negotiate active targeting, the remedial medicine must be conjugated to a towel- or cell-specific ligand using a carrier system. The remedial substance is included in a big patch or nanoparticle that passively travels to the target organ in order to negotiate unresistant targeting[13].

The remedial substance is included in macromolecules or Betsy patches that passively travel to the target organ in order to negotiate unresistant targeting. Through the EPR effect, specifics can be paired with macromolecules or enclosed in nanoparticles to passively target malice. As a cover, nanoparticles can be invested into the organ of interest or muscle pains via tubes[14].

Fig :A Targeted Drug Delivery System

Passive and active targeting system

During their path to the target, nanocarriers encounter a variety of obstacles, including epithelial walls and general uptake. It's pivotal to integrate an introductory understanding of tumour biology with the logical design of nanocarriers in order to report on the challenges associated with using nanotechnology to target tumours[15]. Dense blood vessels and poor lymphatic drainage are two common characteristics of tumours. The increased penetration as well as retention effect(EPR effect) allows a nanocarrier to enter tumour cells through dense highways, while free drugs may diffuse in general[16][17].

The further passable nature of rotation in tumour cells is caused by angiogenesis, which is the fast and defective creation of lately formed vessels from formerly being bones

. also, the tumours ' bloodied lymphatic rotation contributes to the retention of the added up nanocarriers and their capability to distribute specifics into the immediate girding area of the tumour cells. Research employing liposomes with varying average sizes indicates that the minimal vesicle size needed for escape into tumours is roughly 400 nm. still, other examinations have demonstrated that patches with a compass lower than 200 nm are more efficient[18].

unresistant targeting ways, which are grounded on clinical remedy, have numerous disadvantages. Due to the changeable nature of the fashion and the inefficiency of some medicines' prolixity, it isn't always possible to target specific cells within a tumour. This lack of control can lead to multiple- medicine resistance(MDR), a condition in which cases who haven't responded to chemotherapy parade resistance of cancer cells to one or further medicines. The increased product of transporter proteins, which are responsible for removing drugs from cells on the remotest subcaste of cancer cells, leads to MDR P

medicine efficacity is always reduced when expelled from the body, and cancer cells snappily come resistant to a wide range of specifics[19]. The fact that some tumours don't show the EPR effect and that a single tumour's vascular permeability may vary further restricts the mileage of the unresistant approach. An implicit result to these constraints is to alter the nanocarriers so that, upon extravasation, they bind laboriously to particular cells. This can be fulfilled by using a range of the conjugation chemistry to bind targeting agents, similar as ligands — motes that can interact to particular receptors on the cell's face — to the remotest subcaste of the Betsy carriers[20].

Through ligand- receptor relations, nanocarriers will identify the receptor, connect to the target cells, and release the medicine within the cell's membrane. Generally speaking, a targeting agent must bind to motes that have been expressed on the face of cancer cells with high selectivity if it's to deliver Betsy carriers to these cells via targeting. A face marker, similar as an antigen or receptor, should be overproduced on target cells relative to normal cells in order to optimize selectivity[21].

For illustration, the number of receptors should be between 104 and 105 clones per cell in order to effectively transport liposomes that to B- cell antigens exercising theanti-CD19 immunoglobulin(mAb). Targeting those with lower viscosity is less successful. Receptor viscosity of 105 clones per cell of ErbB2 receptors was needed in a bone cancer model to increase the restorative effectiveness of ananti-ErbB2-targeted liposomal doxorubicin in comparison to its on-targeted counterpart[22]. Certain ligands can bind to their receptors, which can lead to receptor- intermediated internalization. This process is constantly needed for the release of specifics from nanocarriers inside of cells. A further notable remedial result was attained when immunoliposomes directed against mortal blood vessel cancer(B- cell carcinoma) were labelled with an absorbinganti-CD19 ligand as opposed to anoninternalizinganti-CD20 ligand[23][24].

In discrepancy, owing to the observer effect targeting nanocarriers To non-internalizing receptors may occasionally be profitable in solid tumours, where cells lacking the target receptor can be killed through medicine release at the face of the neighbouring cells, where carriers can bind. It's generally known that advanced binding affinity increases targeting efficacity[25] still, for solid tumours due to a " list- point wall " high list affinity can drop penetration of nanocarriers, where the nanocarrier binds to its target so mightily that penetration into the towel is averted. In addition to enhanced affinity, multivalent list goods may also be used to ameliorate targeting. The collaborative list in a multivalent commerce is much stronger than monovalent list[26].



Fig: illustration of the various ways that medications can be delivered to tumours via nanocarriers. Targeting of passive tissue in (A) and active cells in (B), respectively.

Types Of Nanoparticles Used As Drug Delivery System

Various kinds of nanoparticles have been suggested, with some being employed for more than one purpose based on the application (i.e., diagnostic, imaging, or therapy). The two primary categories of nanoparticles in this section are both inorganic and organic NPs. Micelles, dendrimers, liposomes, hybrids, and compact polymeric NPs are all included in the initial category. Silica, gold NPs, fullerenes, and tiny quantum dots are in the next group[27].

Micelles are amphiphilic molecules, such as lipids or polymers, assembled into nanostructures. They reveal the hydrophilic molecules and conceal their hydrophobic components inside the structure when exposed to water-based conditions. Conversely, in settings rich in lipids, their structure may assemble in another way. Micelles are structures that undergo a long circulation of blood and are generally stable because of their hydrophobic shell[28].



Fig : Main Types Of Nanoparticles used in Various Application

The structural characteristic of a dendrimer is a branching arrangement originating from a number of cores. The total number of generations that are permitted for development over these cores readily controls the size of these NPs.

Dendrimers are difficult to include and release drugs from since they require a long period to create[29].

Liposomes are particles composed only of lipids. The most prevalent are uniflagellar Liposomes, which typically have a diameter of 100–800 nm27. These cylindrical structures exhibit significant manufacturing

expenses and content leakage since they are composed of hydrophilic chemicals. Their primary benefits include full biodegradability, compatibility, nontoxicity, and non-immunogenicity[30].**w.**

Nanotechnology, known as compressed polymeric nuclei, is composed only of polymers that are either natural or synthetic. Compared to liposomes, they are often more stable, enabling weeks of continuous targeted drug administration with less drug leakage. At last, ionic linkage between the medicinal drug and these polymer nanoparticles may occur. As a substitute, it may break down, entrap, adsorbed at the surface of nanoparticles (NPs), or be encased in a polymeric shell (nano capsules)[31].

For the production of NPs, inorganic ele~~ments like silic~~a, gold, silver, and platinum can also be employed[32].Various techniques can ~~be employed to~~ create inorganic nanoparticles (NPs), which consist of metal or covalently b~~ound atoms arr~~anged in a hard and highly organized three-dimensional structure[33]. Unlik~~e organic NPs~~, their characteristics—like size and shape—are largely unaffected by the ~~in vivo environ~~ment. However, the disadvantages of inorganic NPs mu~~st be co~~nsidered[34][35].

It is necessary to take into account th~~e inability of lo~~ading medications into the molecular makeup of me~~tallic~~ nanoparticles as well as ~~any~~ potential adverse effects i~~n blood~~. Nonetheless, their significant potential as magnetical~~ly sensitive none~~ntities has been thoroughly examined in the re~~sear~~ch[36].

Application of Nanopart~~icle used in~~ Drug Delivery system

The rapid progress of biotechnology ushers in a new age for humankind. Novel drug delivery strategies are needed for new biological therapeutics like amino acids and proteins in order to reduce adverse effects and improve compliance among patients[37].For new medications, the market also requires innovative and effective drug delivery systems. It is estimated that around

40% of all pharmaceutical sales in 2007 came from the drug delivery business[38][39].Pharmaceutical businesses are also creating new product formulations in response to impending patent expirations. This is made possible by innovative drug delivery methods[40].By using novel delivery systems like nanotechnology, pharmaceutical enterprises can create new formulations of medications that are currently off-patent or soon to be offpatent[41].Reformulated medications using novel ways to deliver drugs avoid the need for lengthy clinical trials, resulting in savings in costs for the healthcare system. Novel drug delivery methods could also make it possible to use biologics or some compounds that were previously unfeasible due to their toxicity and quick elimination[42][43]. Researchers will keep working on developing new strategies for delivering macromolecules, which will help produce new biologic products, including proteins and vaccinations[44][45]. In the meantime, novel drug delivery strategies will be necessary for gene treatments to succeed. Over 300 Americanbased firms are engaged in the development of novel drug delivery systems, as the efficacy of medicine is significantly influenced by its mode of delivery[46][47].Here, the potential use of such nanoparticles in medication delivery via various delivery channels and therapeutic areas will be highlighted[48].

~~1~~. Applications of Nanoparticles in Different Therapeutic Areas

A particular field of nanotechnology that is benefiting from major expenditures in nanoscale investigation is nanotechnology in medicine. The creation of tailored delivery systems for drugs and diagnostic techniques based on particle design is one area of the field of nanomedicine. In clinical settings, research on the transport and modification of nanoparticles is crucial, particularly when it comes to nanoparticles' controlled penetration of cells[49].The ability of drug-loaded nanoparticles to extend their circulation time facilitates the passive targeting of pharmaceuticals to regions where diseases or inflammation increase local vascular permeability and boost local extravasations into adjacent tissue. We'll touch on some of these and other special qualities of nanoparticles that have enormous therapeutic potential for treating various illnesses[50].

~~2~~. Application of Nano~~particle~~s in Gene Therapy

A growing variety of novel techniques for illness prevention, diagnosis, and therapy have been made possible by advances in the genetic, molecular, and physiological sciences. Gene therapy is a cutting-edge therapeutic strategy intended to either compensate for the genetic flaw in cells or offer more protection[51]. Gene therapy approaches for tumours that are solid, for instance, can be categorized according to their ability to block neo-angiogenesis, confer drug sensitivity, stimulate anti-tumour immunity, or re-establish cellular growth control. To effectively express recorded enzymes at the target site by in vivo gene transfer, novel delivery carriers that can deliver medicinal genes locally or systemically to a particular region must be developed[52][53]. The use of nanoparticles in gene therapy is becoming more and more significant. Due to their adaptability, simplicity in planning, and ability to safeguard enclosed plasmid DNA, nanoparticulate assemblies are appealing as gene delivery vehicles[54]. They are effective at protecting plasmids while they are in the systemic circulation and encapsulating a range of plasmid sizes[55].Additionally, after systemic delivery, they can be directed toward

particular bodily cell types and tissues to evade absorption by the mononuclear phagocytic system. Because of their charge and size, nanoparticles can be engineered to travel to a specific location. Because of their high surface area-to-volume ratio, nanoparticles can effectively enclose DNA even when it hasn't been recondensed[56].

3. Application of Nanoparticles in Cancer Therapy

Treating tumours that are solid locally seems to be one of the main benefits of healthcare delivery systems based on nanoparticles[57].The potential for passive collection of systemically administered nanoparticles (20–150 nm) from leaky vasculature is made possible by novel nanoparticle delivery technologies[58].Tumour microvasculature is discontinuous and leaky, with bigger pores (diameters of 100–1000 nm) that allow nanostructured vehicles to pass through them[59]. For instance, nanoparticles usually diffuse across very small distances from the circulation into the nearby parenchyma[60].In the meantime, nanoparticles larger than the extracellular space found in normal tissue but shorter than the small pores of the vascular system of tumours may be used to specifically target malignancies[61]. **1. Conclusion**

The healthcare sector could greatly benefit from the technical advancements brought about by nanotechnology. This review covered a number of advancements in the use of nanoparticles in tissue engineering and medication delivery. The therapeutic index of pharmaceuticals has been somewhat enhanced by the currently authorized nanoparticle-based therapeutic platforms, either by lowering medication toxic effects, minimizing side effects, or increasing treatment efficacy. The antibodies, peptides, or aptamers—targeting ligands—will be included in the next generation of nanoparticle systems, potentially increasing their efficacy or lowering their toxicities. Future exploratory research should focus on developing more sophisticated systems, including multimodal nanoparticles, which can simultaneously be used for imaging, treatment, and targeting.

2. References

1. Society AC. 2007. Breast cancer facts & figures. Atlanta (GA): American Cancer Society. [Google Scholar]
2. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004;122:598–609. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
3. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–1316. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
4. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207. [Crossref] [PubMed], [Google Scholar]
5. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750–763. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
6. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688–701. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
7. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161–171. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
8. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target- specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318. [PubMed] [Web of Science ®], [Google Scholar]
9. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42:463–478. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
10. Harris JM, Martin NE, Modi M. Pegylation. Clin Pharmacokinet. 2001;40:539–551. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
11. Wisse E, Braet F, Luo D, et al. Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol. 1996;24:100–111. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
12. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752–3756. [PubMed] [Web of Science ®], [Google Scholar]
13. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23:1417–1450. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]

14. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother. 2004;58:168–172. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
15. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392. [PubMed] [Web of Science ®], [Google Scholar]
16. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–160. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
17. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607–4612. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
18. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATPdependent transporters. Nat Rev Cancer. 2002;2:48–58. [Crossref] [PubMed] [Web of Science ®], [Google Scholar] 2006;237:180–187. [Crossref] [PubMed] [Web of Science ®], [Google Scholar] 65. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
19. Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett.
20. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58–
21. de Menezes DEL, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998;58:3320–3330. [PubMed] [Web of Science ®], [Google Scholar]
22. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes. Clin Cancer Res. 2002;8:1172–1181. [PubMed] [Web of Science ®], [Google Scholar]
23. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6:559–565. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
24. Peer D, Zhu P, Carman CV, et al. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen1. Proc Natl Acad Sci USA. 2007;104:4095–4100. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
25. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62:7190–7194. [PubMed] [Web of Science ®], [Google Scholar]
26. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 1994;15:215–220. [Crossref] [PubMed] [Web of Science ®], [Google Scholar]
27. Parveen S, Misra R, Sahoo S. Nanopar3cles: a boon to drug delivery, therapeu3cs, diagnos3cs and imaging. Nanomedicine Nanotechnology, Biol. Med. 2012;8(2):147- 166.
28. Orive G, Anitua E, Pedraz J, Emerich D. Biomaterials for promo3ng brain protec3on, repair and regenera3on. Nat. Rev. Neurosci. 2009;10(9):682-692.
29. Adair J, PareSe M, Erhan I, Kester M. Nanopar3culate alterna3ves for drug delivery. ACS Nano 2010;4(9):4967-4970.
30. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classifica3on, prepara3on, and applica3ons. Nanoscale Res. LeS. 2013;8(102):1-9.
31. Reis C, Neufeld R, Ribeiro A, Veiga F. Nanoencapsula3on I. Methods for prepara3on of drug-loaded polymeric nanopar3cles. Nanomedicine 2006;2(1):8-21.
32. Kim T, Hyeon T. Applica3ons of inorganic nanopar3cles as therapeu3c agents. Nanotechnology 2014;25(1):1 -14.
33. De Jong W, Borm P. Drug delivery and nanopar3cles: applica3ons and hazards. Int. J. Nanomedicine 2008;3(2):133 -149.
34. Mishra D, Hubenak J, Mathur A. Nanopar3cle systems as tools to improve drug delivery and therapeu3c efficacy. J Biomed Mater Res A. 2013;101(12):1 -15.

35. Santo V, Rodrigues M, Gomes M. Contribu3ons and future perspec3ves on the use of magne3c nanopar3cles as diagnos3c and therapeu3c tools in the field of regenera3ve medicine. Expert Rev. Mol. Diagn. 2013;13(6):553 -566.

36. Lin W, Huang Y -W, Zhou X -D, Ma Y. In vitro toxicity of silica nanopar3cles in human lung cancer cells. Toxicol. Appl. Pharmacol. 2006;217(3):252 -259

37. Bradbury J. Beyond pills and jabs. Researchers develop new ways to get drugs to the right place at the right time. Lancet. 2003;362:1984.

38. LangerR. New methods of drug delivery. Science. 1990;249:1527.

39. Wang Q, Zhang N, Hu X, Yang J, Du Y. Alginate/polyethylene glycol blend fibers and their properties for drug controlled release. Journal of Biomedical Materials Research Part A. 2007;82:122-8.

40. WANG Q, DU Y-m, FAN L-h, LIU H, WANG X-h. Structures and Properties of ChitosanStarch-Sodium Benzoate Blend Films [J]. Wuhan University Journal (Natural Science Edition). 2003;6:013.

41. Henry C. New wrinkles in drug delivery. Chemical and engineering news. 2004;82:37.

42. VisionGain. Drug delivery 2003: new technologies in the global market. VisionGain. 2003;June.

43. CINDY H. Special delivery: pharmaceutical companies aim to target their drugs with nano precision. Mechanical Engineering. 2004;126:10-2.

44. Dass C, Su T. Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from genotherapy. Drug Delivery. 2001;8:191-213.

45. LaVan D, Lynn D, LangerR. Moving smaller in drug discovery and delivery. NatureReviews Drug Discovery. 2002;1:77-84.

46. LaVan D, McGuire T, LangerR. Small-scale systems for in vivo drug delivery. Naturebiotechnology. 2003;21:1184-91.

47. El-Aneed A. An overview of current delivery systems in cancer gene therapy. Journal of Controlled Release. 2004;94:1-14.

48. D'Aquino R. Good drug therapy: it's not just the molecule- it's the delivery. Chemical Engineering Progress. 2004;100

49. FreitasR. Nanomedicine, Volume I: Basic Capabilities: Landes Bioscience; 1999.

50. Escriou V, Carrière M, Scherman D, Wils P. NLS bioconjugatesfor targeting therapeutic genes to the nucleus. Advanced drug delivery reviews.

51. 2003 Baselga J. New horizons: gene therapy for cancer. Anti-Cancer Drugs. 1999;10:S39.

52. 52.Folkman J. Antiangiogenic gene therapy. Proceedings of the National Academy ofSciences of the United States of America. 1998;95:9064.

53. Huber B. Gene therapy strategies for treating neoplastic disease. Annals of the New York Academy of Sciences. 1994;716:6-11.

54. Roth J, Cristiano R. Gene therapy for cancer: what have we done and where are we going? JNCI Journal of the National Cancer Institute. 1997;89:21.

54. Amiji M. Polymeric gene delivery: Principles and applications: CRC; 2004 Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al.

55. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. Journal of Controlled Release. 2005;108:193-214. Qun Wang 34

56. Lockman P, Mumper R, Khan M, Allen D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug development and industrial pharmacy. 2002;28:1-13.

57. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal

58. Doxorubicin: reviewof animaland humanstudies. Clinical pharmacokinetics.

59. 2003;42:419-36.

60. Allen T, Cullis P. Drug delivery systems: entering the mainstream. Science.

61. Gabizon A, Shmeeda H, Horowitz A, Zalipsky S. Tumor cell targeting of folic acid-PEG liposome-

62. entrapped drugs with phospholipid-anchored conjugates. Advanced

63. A drug delivery reviews. 2004;56:1177-92.